GPC Biotech and Boehringer Ingelheim Collaborate on Drug Target Project | GenomeWeb

NEW YORK, Jan 9 – GPC Biotech has signed on to a proteomics and genomics deal with Boehringer Ingelheim pharmaceuticals, in which GPC will identify targets and pathways associated with human papillomavirus, GPC announced Tuesday.

In this project, GPC Biotech is using OliCode molecular cloning technology, PathCode yeast two-hybrid protein-protein interaction identification technology, and its bioinformatics applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.